AU2022376773A1 - Pyridyl-containing compound - Google Patents
Pyridyl-containing compound Download PDFInfo
- Publication number
- AU2022376773A1 AU2022376773A1 AU2022376773A AU2022376773A AU2022376773A1 AU 2022376773 A1 AU2022376773 A1 AU 2022376773A1 AU 2022376773 A AU2022376773 A AU 2022376773A AU 2022376773 A AU2022376773 A AU 2022376773A AU 2022376773 A1 AU2022376773 A1 AU 2022376773A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- group
- alternatively
- mixture
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111269381.X | 2021-10-29 | ||
| CN202111269381 | 2021-10-29 | ||
| CN202210233624.2 | 2022-03-10 | ||
| CN202210233624 | 2022-03-10 | ||
| CN202210849103.X | 2022-07-19 | ||
| CN202210849103 | 2022-07-19 | ||
| CN202211274771.0 | 2022-10-18 | ||
| CN202211274771 | 2022-10-18 | ||
| PCT/CN2022/128251 WO2023072248A1 (zh) | 2021-10-29 | 2022-10-28 | 含吡啶基的化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022376773A1 true AU2022376773A1 (en) | 2024-05-23 |
Family
ID=86159245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022376773A Pending AU2022376773A1 (en) | 2021-10-29 | 2022-10-28 | Pyridyl-containing compound |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250002472A1 (https=) |
| EP (1) | EP4424676A4 (https=) |
| JP (1) | JP2024539922A (https=) |
| KR (1) | KR20240090588A (https=) |
| CN (1) | CN118055924A (https=) |
| AU (1) | AU2022376773A1 (https=) |
| CA (1) | CA3235436A1 (https=) |
| IL (1) | IL312179A (https=) |
| MX (1) | MX2024004871A (https=) |
| TW (1) | TW202321220A (https=) |
| WO (1) | WO2023072248A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121039118A (zh) * | 2023-04-28 | 2025-11-28 | 正大天晴药业集团股份有限公司 | 含三唑基的化合物 |
| WO2026082075A1 (zh) * | 2024-10-15 | 2026-04-23 | 杭州百诚医药科技股份有限公司 | 丙烯酰胺类化合物及其医药用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03421B (me) * | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba |
| US10526295B2 (en) * | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2019232724A1 (en) * | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
| CN110592141B (zh) * | 2018-06-13 | 2023-07-07 | 中国科学院上海有机化学研究所 | 用于调控基因编辑效率的化合物及其应用 |
| WO2020092965A1 (en) * | 2018-11-01 | 2020-05-07 | Karyopharm Therapeutics Inc. | E2f1 as a biomarker for treatments using xpo1 inhibitors |
| WO2021252900A1 (en) * | 2020-06-11 | 2021-12-16 | Karyopharm Therapeutics Inc. | Biomarkers for response to exportin-1 inhibitors in multiple myeloma patients |
| CN112538069A (zh) * | 2020-11-05 | 2021-03-23 | 苏州艾和医药科技有限公司 | 一种氮唑类衍生物或其药物可接受盐及其制备方法和用途 |
| CN113045550A (zh) * | 2021-03-12 | 2021-06-29 | 深圳济康医药科技有限公司 | 一种三氮唑类衍生物及其制备方法和应用 |
| CN113248474A (zh) * | 2021-05-24 | 2021-08-13 | 王能能 | 五元氮唑杂环衍生物及其制备方法和用途 |
-
2022
- 2022-10-28 CA CA3235436A patent/CA3235436A1/en active Pending
- 2022-10-28 WO PCT/CN2022/128251 patent/WO2023072248A1/zh not_active Ceased
- 2022-10-28 AU AU2022376773A patent/AU2022376773A1/en active Pending
- 2022-10-28 KR KR1020247016666A patent/KR20240090588A/ko active Pending
- 2022-10-28 IL IL312179A patent/IL312179A/en unknown
- 2022-10-28 EP EP22886123.3A patent/EP4424676A4/en active Pending
- 2022-10-28 US US18/703,482 patent/US20250002472A1/en active Pending
- 2022-10-28 JP JP2024523981A patent/JP2024539922A/ja active Pending
- 2022-10-28 CN CN202280066733.8A patent/CN118055924A/zh active Pending
- 2022-10-28 MX MX2024004871A patent/MX2024004871A/es unknown
- 2022-10-28 TW TW111141120A patent/TW202321220A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023072248A1 (zh) | 2023-05-04 |
| JP2024539922A (ja) | 2024-10-31 |
| CN118055924A (zh) | 2024-05-17 |
| CA3235436A1 (en) | 2023-05-04 |
| IL312179A (en) | 2024-06-01 |
| TW202321220A (zh) | 2023-06-01 |
| EP4424676A1 (en) | 2024-09-04 |
| MX2024004871A (es) | 2024-05-06 |
| US20250002472A1 (en) | 2025-01-02 |
| KR20240090588A (ko) | 2024-06-21 |
| EP4424676A4 (en) | 2025-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113024544B (zh) | 一种含氰基并杂环化合物及其用途 | |
| JP7046940B2 (ja) | 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物 | |
| KR102215172B1 (ko) | 이미다조피라진아민 페닐 유도체 및 그의 용도 | |
| CN113666923A (zh) | 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用 | |
| WO2022199586A1 (zh) | 嘧啶并吡啶类抑制剂及其制备方法和应用 | |
| WO2021249563A1 (zh) | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 | |
| AU2018314980B2 (en) | Diarylthiohydantoin compound as androgen receptor antagonist | |
| CN112851663B (zh) | 一种并杂环化合物及其用途 | |
| AU2022376773A1 (en) | Pyridyl-containing compound | |
| WO2022135591A1 (zh) | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 | |
| KR20230015944A (ko) | Ret 키나아제 억제제로 사용되는 화합물 및 이의 용도 | |
| CN118382626A (zh) | 蛋白激酶抑制剂及其制备方法和应用 | |
| CA3134405A1 (en) | Thienoheterocyclic derivative, preparation method therefor and medical use thereof | |
| AU2019339994B2 (en) | Furo[3,4-b]pyrrole-containing BTK inhibitor | |
| CN113801113A (zh) | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 | |
| EP4289833A1 (en) | Tyk2 inhibitor compound containing bicyclic ring | |
| EP4617272A1 (en) | Fused bicyclic compound | |
| CN115925689A (zh) | 含环丙基的核输出蛋白抑制剂 | |
| CN116813646A (zh) | 取代桥环类抑制剂及其制备方法和应用 | |
| EA051207B1 (ru) | Пиридилсодержащее соединение | |
| HK40111379A (en) | Pyridyl-containing compound | |
| CN116730984A (zh) | 含吡啶基的化合物 | |
| CN112209933B (zh) | 含有4-氮杂螺庚烷的btk抑制剂 | |
| AU2023212227A1 (en) | Hydrazino group-containing compound | |
| WO2022182731A1 (en) | Sn-labeling and radiolabeling of epichaperome inhibitors |